来那度胺联合R-CHOP改善初诊弥漫大B细胞淋巴瘤结局:随机II期US Intergroup研究ECOG-ACRIN E1412
PURPOSE: Lenalidomide combined with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (R2CHOP) in untreated diffuse large B-cell lymphoma (DLBCL) has shown promising activity, particularly in the activated B-cell-like (ABC) subtype.…
要点
- R2CHOP较R-CHOP显著改善初诊DLBCL的PFS,3年PFS 73% vs 61%。
核心结论
- 在信号探索性研究中,来那度胺加入R-CHOP(R2CHOP)改善了初诊DLBCL患者的结局,包括ABC-DLBCL亚型。
研究设计与样本
- ECOG-ACRIN E1412为随机II期研究,比较R2CHOP与R-CHOP在初诊DLBCL中的疗效。
- 主要终点为全部患者PFS,共同主要终点为ABC-DLBCL的PFS;肿瘤采用NanoString Lymph2Cx进行细胞起源分析。
主要发现
- R2CHOP组骨髓抑制更常见。
关键数值与推荐
- 入组标准:初诊DLBCL,II期大肿块-IV期,IPI≥2,ECOG PS≤2。
- 治疗方案:R2CHOP或R-CHOP,共6个周期。
- 可评估280例中,ABC-DLBCL 94例,GCB-DLBCL 122例,不可分类18例,未知46例。
临床怎么用
- 对于初诊DLBCL(II期大肿块-IV期、IPI≥2、ECOG PS≤2),可考虑在R-CHOP基础上加用来那度胺以提高PFS。
- 治疗前应进行细胞起源分析以识别ABC-DLBCL亚型,该亚型可能从R2CHOP中获益。
- 需注意R2CHOP组骨髓抑制更常见,应加强血液学毒性监测。
局限性
- 本研究为信号探索性随机II期研究,样本量有限(可评估280例)。
- 中位随访3.0年,长期生存获益需进一步随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Lenalidomide combined with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (R2CHOP) in untreated diffuse large B-cell lymphoma (DLBCL) has shown promising activity, particularly in the activated B-cell-like (ABC) subtype. Eastern Cooperative Oncology Group (ECOG)-ACRIN trial E1412 was a randomized phase II study comparing R2CHOP versus R-CHOP in untreated DLBCL. PATIENTS AND METHODS: Patients with newly diagnosed DLBCL, stage II bulky-IV disease, International Prognostic Index (IPI) ≥ 2, and ECOG performance status ≤ 2 were eligible and randomly assigned 1:1 to R2CHOP versus R-CHOP for six cycles. Tumors were analyzed using the NanoString Lymph2Cx for cell of origin. The primary end point was progression-free survival (PFS) in all patients with the co-primary end point of PFS in ABC-DLBCL. Secondary end points included overall response rate (ORR), complete response (CR) rate, and overall survival (OS). RESULTS: Three hundred forty-nine patients were enrolled; 280 patients (145 R2CHOP and 135 R-CHOP) were evaluable: 94 were ABC-DLBCL, 122 germinal center B-cell-like-DLBCL, 18 unclassifiable, and 46 unknowns. Baseline characteristics were well-balanced between arms, and the median age was 66 (range, 24-92); 70% of patients had stage IV disease; 34%, 43%, and 24% had IPI 2, 3, and 4 or 5, respectively. Myelosuppression was more common in the R2CHOP arm. The ORR and CR rate were 92% and 68% in R-CHOP and 97% (P = .06) and 73% (P = .43) in the R2CHOP arm, respectively. The median follow-up was 3.0 years; R2CHOP was associated with a 34% reduction in risk of progression or death versus R-CHOP (hazard ratio [HR], 0.66 95% CI, 0.43 to 1.01) and 3-year PFS of 73% versus 61%, one-sided P = .03, and an improvement in OS (83% and 75% at 3 years; HR, 0.67; one-sided P = .05). The PFS HR for R2CHOP was 0.67 for ABC-DLBCL, one-sided P = .1. CONCLUSION: In this signal-seeking study, the addition of lenalidomide to R-CHOP (R2CHOP) improved outcomes in newly diagnosed DLBCL including patients with ABC-DLBCL.
引用
- Nowakowski GS, Hong F, Scott DW, et al. Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. J Clin Oncol. 2021. PMID: 33555941. doi:10.1200/JCO.20.01375
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。